newsfilter
← Latest News
GlobeNewswire·

Icosavax Initiates Phase 2 Trial of IVX-A12 Against RSV and hMPV in Older Adults

- Phase 2 topline interim results expected in 1Q 2024 - - 6-month durability data for Phase 1 trial of IVX-A12 also expected in 1Q 2024 - SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc.